ReCode Achieves First Clinical Success for Inhaled mRNA Therapy in PCD
MENLO PARK, California, May 20, 2026 ReCode Therapeutics announced positive clinical data from its RCT1100 inhaled mRNA therapy program...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MENLO PARK, California, May 20, 2026 ReCode Therapeutics announced positive clinical data from its RCT1100 inhaled mRNA therapy program...
